Results 191 to 200 of about 11,749,172 (291)

Distinct Neuropsychiatric Profiles Associated With 17p11.2 Deletions and RAI1 Variants in Smith–Magenis Syndrome

American Journal of Medical Genetics Part A, Volume 200, Issue 10, Page 2320-2330, October 2026.
ABSTRACT Smith–Magenis syndrome (SMS) results from either a recurrent 17p11.2 deletion or pathogenic variants in the retinoic acid induced 1 gene (RAI1). While neurodevelopmental impairment and behavioral dysregulation are well recognized, systematic genotype‐stratified analyses across psychiatric domains remain limited.
Albin Blanc, Christophe Nemos, Céline Bonnet, Mathilde Renaud, Sandra Chapuis, Pauline Boiroux, Marie‐Noëlle Babinet, Caroline Demily   +7 more
wiley   +1 more source

Long-term forecasting of the impact of EV home charging at different adoption rates on the Egyptian load profile. [PDF]

Sci Rep
Beshay DSR, Shafei MAR, Ibrahim DK.
europepmc   +1 more source

Genetic Risk and High Burden of Depression and Suicide in the Maya‐Mestizo Population of Yucatán, México

American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, Volume 201, Issue 7, Page 431-440, October 2026.
ABSTRACT Major depression and suicide are critical public health concerns, particularly in underrepresented populations with unique genetic and sociocultural contexts. The Maya‐mestizo population presents the highest suicide rates in the country but remains understudied in psychiatric genetics. This study evaluated the association between three genetic
Marta Menjivar, Erandi Bravo, Margarita Rivera‐Balancan, Barbara Itzel Pena Espinoza   +3 more
wiley   +1 more source

Repurposing semaglutide as an adjunctive treatment for cocaine use disorder: protocol for a randomised controlled trial. [PDF]

BMJ Open
Yammine L, Versace F, Green CE, Webber HE, Yoon JH, Gutierrez AD, Leonard SJ, Weaver MF, Schmitz J.   +8 more
europepmc   +1 more source

A latent class analysis of clinical complexity: Secondary analysis of the collaboration leading to addiction treatment and recovery from other stresses (CLARO) randomized trial

Addiction, Volume 121, Issue 10, Page 2833-2844, October 2026.
Abstract Background and aims Individuals with opioid use disorder (OUD) frequently present with co‐occurring mental health conditions such as depression and posttraumatic stress disorder (PTSD), along with other mental health substance use disorders, physical health conditions and social determinants that together comprise ‘clinical complexity ...
Megan S. Schuler, Rebecca Weir, Colleen M. McCullough, Grace M. Hindmarch, Beth Ann Griffin, Kirsten Becker, Lisa S. Meredith, Katherine E. Watkins   +7 more
wiley   +1 more source

Multi objective moth swarm algorithm for optimizing electric vehicle integration in distribution grids. [PDF]

Sci Rep
Azadikhouy M.
europepmc   +1 more source

Collaborative care intervention for risky opioid use among primary care patients: The STOP randomized clinical trial

Addiction, Volume 121, Issue 10, Page 2807-2821, October 2026.
Abstract Background and aims Individuals who engage in illicit or nonmedical opioid use may have elevated risk of health and social consequences, including progression to opioid use disorder (OUD). Preventive interventions to reduce this risk are lacking. This trial tested the impact of a primary care‐integrated collaborative care approach for reducing
Jennifer McNeely, Geetha A. Subramaniam, Rebecca Stone, Shayna Mazel, Noa Appleton, Yasna Rostam‐Abadi, Amanda M. Bunting, Yidan Shi, Travis I. Lovejoy, Lillian Gelberg, Donna Beers, Margaret Kline, Song Zhang, Tobie Kim, Ashley Case, Jennifer McCormack, Michael A. Incze, Jane M. Liebschutz, the STOP trial site principal investigators, Karen Alexander, Seuli Bose Brill, Sarah Kawasaki, Adam J. Gordon, Hyunouk Hong   +23 more
wiley   +1 more source

New and old challenges for clinical psychology and psychotherapy toward 2030. [PDF]

Front Psychol
Castelnuovo G.
europepmc   +1 more source

Muscarinic agonists for schizophrenia: Bridging preclinical evidence and clinical enthusiasm

British Journal of Pharmacology, Volume 183, Issue 19, Page 5701-5731, October 2026.
Abstract Antipsychotic drugs targeting dopamine receptors have been used to treat schizophrenia for decades, primarily alleviating positive symptoms such as hallucinations and delusions. However, they provide limited benefit for cognitive and negative symptoms—major contributors to poor outcomes—and are frequently associated with significant side ...
Brian J. Morris, Judith A. Pratt
wiley   +1 more source

A HLBDA, GA, and COA for optimal operation of distributed energy resources. [PDF]

PLoS One
Alhasnawi BN, Mlkat Almutoki SM, Hashim HK, Sadeq AM, Almousawi AQ, Jasim BH, Homod RZ, Hussain FFK, Al-Shareeda MA, Dočekalová A, Bureš V.   +10 more
europepmc   +1 more source